A PSEN1 genetic test looks for mutations in the presenilin-1 gene, the most common known cause of early-onset Alzheimer's disease that runs in families. Doctors order it for people who develop dementia symptoms before about age 65, usually in their 30s to 50s, and who have relatives with a similar pattern of early illness — it is not a general test for ordinary memory complaints or late-life Alzheimer's, according to Pathology Tests Explained. This matters because a positive or negative result changes more than one person's diagnosis. PSEN1 mutations pass through families in a predictable pattern, so the result carries direct implications for siblings and children, not just the person being tested.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Actually Qualifies For This Test
- How Accurate Is the Result, and What a Negative Result Does Not Mean
- How to Prepare Before Testing
- What Happens After a Result Comes Back
- Frequently Asked Questions
Who Actually Qualifies For This Test
PSEN1 testing is aimed at a narrow group: people with dementia symptoms that began well before typical retirement age, paired with a family history that looks autosomal dominant — meaning parents, siblings, aunts, uncles, or grandparents who developed dementia unusually young across more than one generation. Memory problems alone, without that early onset and family pattern, do not meet the threshold Pathology Tests Explained describes. A second group also qualifies: adult relatives of someone who already has a confirmed PSEN1, PSEN2, or APP mutation.
This is called predictive testing, and it is generally restricted to people 18 or older with a first- or second-degree relative carrying an identified mutation, according to Highmark's medical policy on genetic testing for Alzheimer's disease. Predictive testing requires formal pre-test and post-test counseling before a sample is even drawn. PSEN1 is tested first in these workups because it is the gene most frequently responsible for familial early-onset Alzheimer's — estimates range from roughly 20% to 70% of diagnosed cases, depending on the cohort studied — which is why clinical protocols check it before PSEN2 or APP, per Genomics England PanelApp's Early-onset Dementia panel.
How Accurate Is the Result, and What a Negative Result Does Not Mean
Accuracy depends heavily on who is being tested. Among people selected specifically for strong family history and very young onset, next-generation sequencing panels covering PSEN1, PSEN2, and APP find a causative variant in up to about 18% of cases. In broader early-onset Alzheimer's groups that are not pre-screened for family history, the detection rate drops to as low as 1.5%, according to a PMC exome sequencing study and the Giau et al. 2019 study in Scientific Reports. A negative result does not rule out a hereditary cause.
Even a comprehensive early-onset gene panel identifies a known pathogenic variant in only about 60% to 80% of cases that are clinically suspected to be hereditary based on family history, according to ARUP Laboratories' test documentation. That gap exists because some families carry mutations in genes not yet identified or not covered by standard panels. When a mutation is found, it carries a different weight than most genetic test results. PSEN1 mutations are highly penetrant, meaning carriers face a lifetime disease risk generally cited above 95%, with onset typically in the 30s to 50s. This sets PSEN1 apart from lower-penetrance risk genes like APOE, which raise risk without making the disease near-certain.
How to Prepare Before Testing
Preparation starts with genetic counseling, not a blood draw. The reference standard for this testing — issued jointly by the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors in 2011 and still cited in payer policy today — states that testing for early-onset autosomal dominant Alzheimer's should happen only alongside genetic counseling, modeled on the protocol used for Huntington's disease testing since 1994, according to Blue Shield of California's medical policy document. A counselor will ask for a detailed family history before ordering anything — ages of onset, confirmed diagnoses, and which relatives are living or available for comparison.
For someone already showing symptoms, this history helps decide whether PSEN1 is the right first gene to test. For an asymptomatic adult relative, counseling before the sample is drawn is required, not optional, because the result is predictive rather than diagnostic. Practical steps to take before an appointment:.
- Gather exact ages of onset and diagnoses for affected relatives, not just "early" or "young."
- Note whether any relative has already had genetic testing, and request those results if possible — testing a relative first, when feasible, narrows what needs to be checked.
- Expect a session that covers what a positive result means for insurance, employment, and family planning, not just the lab mechanics.
- Plan for the result to take weeks, not days, since confirmatory sequencing and counseling scheduling both add time.
What Happens After a Result Comes Back
A confirmed PSEN1 mutation changes the conversation for the person tested and for their biological children. Each child of a confirmed carrier has a 50% chance of inheriting the mutation, consistent with autosomal dominant inheritance, according to Top Doctors UK's entry on PSEN1. That statistic is often the first thing families want clarified, and a counselor will walk through what it does and does not mean for each individual relative. Confirmed carriers, including those who are still cognitively unimpaired, are the population targeted by research programs such as the Dominantly Inherited Alzheimer Network, or DIAN, and its associated DIAN-TU prevention trials. This research has shown that amyloid plaque buildup and other brain changes can begin 10 to 20 years before symptoms appear, according to DIAN's observational study page at Washington University.
That lead time is part of why some asymptomatic carriers choose to enroll in observational or treatment trials rather than wait for symptoms. Emotional outcomes do not track neatly with the result itself. A study following people after PSEN1-related testing found that those who tested negative reported distress levels one year later similar to those who tested positive, according to a PMC review on genetic counseling in dementia. Survivor guilt, continued worry about other relatives, and uncertainty about what a negative result means for family members who have not been tested all contribute to this. Post-test counseling sessions are built around this finding, continuing contact after the result rather than ending at disclosure.
Frequently Asked Questions
Can someone get PSEN1 testing just because they're worried about memory lapses?
Standard protocols reserve PSEN1 testing for dementia onset before about age 65 with a family history suggesting autosomal dominant disease, not general memory concerns, according to Pathology Tests Explained.
If PSEN1 comes back negative, is hereditary Alzheimer's ruled out?
No. Even a full early-onset gene panel confirms a known mutation in only about 60% to 80% of clinically suspected hereditary cases, per ARUP Laboratories.
Does a parent's confirmed PSEN1 mutation mean their children will definitely develop Alzheimer's?
Each child has a 50% chance of inheriting the mutation itself, not a 50% chance of a milder outcome, according to Top Doctors UK; carriers then face a lifetime risk generally cited above 95%.
